KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company employs 24 people and reports annual revenue exceeding $50 million. KalVista Pharmaceuticals is focused on developing and commercializing oral medications designed to improve the lives of patients with various diseases. The company specializes in creating oral protease inhibitor drugs based on their deep understanding of the kallikrein-kinin system. Their current focus is on sebetralstat, an investigational drug being developed for the treatment of hereditary angioedema (HAE), a rare genetic disorder that causes debilitating episodes of tissue swelling. HAE can be life-threatening, and KalVista aims to provide a new treatment option for patients suffering from this condition. KalVista Pharmaceuticals distinguishes itself through its commitment to rigorous scientific research and development. The company believes that its expertise in the kallikrein-kinin system provides a unique platform for developing innovative therapies for a range of diseases. For more information about KalVista Pharmaceuticals and its groundbreaking work, please visit their website at kalvista.com.